Evotec Se Adr Stock Cash Per Share
| EVO Stock | USD 4.83 0.07 1.47% |
Evotec SE ADR fundamentals help investors to digest information that contributes to Evotec SE's financial success or failures. It also enables traders to predict the movement of Evotec Stock. The fundamental analysis module provides a way to measure Evotec SE's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evotec SE stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 3.41 | 3.75 |
Evotec | Cash Per Share |
Evotec SE ADR Company Cash Per Share Analysis
Evotec SE's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Evotec SE Cash Per Share | 2.33 X |
Most of Evotec SE's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evotec SE ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Evotec Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Evotec SE is extremely important. It helps to project a fair market value of Evotec Stock properly, considering its historical fundamentals such as Cash Per Share. Since Evotec SE's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evotec SE's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evotec SE's interrelated accounts and indicators.
Click cells to compare fundamentals
Evotec Cash Per Share Historical Pattern
Today, most investors in Evotec SE Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Evotec SE's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Evotec SE cash per share as a starting point in their analysis.
Evotec SE Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Evotec Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, Evotec SE ADR has a Cash Per Share of 2.33 times. This is 46.44% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash per share for all United States stocks is 53.49% higher than that of the company.
Evotec Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evotec SE's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evotec SE could also be used in its relative valuation, which is a method of valuing Evotec SE by comparing valuation metrics of similar companies.Evotec SE is currently under evaluation in cash per share category among its peers.
Evotec SE Current Valuation Drivers
We derive many important indicators used in calculating different scores of Evotec SE from analyzing Evotec SE's financial statements. These drivers represent accounts that assess Evotec SE's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evotec SE's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.7B | 3.5B | 4.7B | 2.7B | 3.8B | 4.0B | |
| Enterprise Value | 2.7B | 3.6B | 4.7B | 2.8B | 3.9B | 4.1B |
Evotec SE ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evotec SE's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evotec SE's managers, analysts, and investors.Environmental | Governance | Social |
Evotec Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0177 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 1.79 B | ||||
| Shares Outstanding | 355.11 M | ||||
| Shares Owned By Institutions | 2.19 % | ||||
| Number Of Shares Shorted | 449.7 K | ||||
| Price To Earning | 444.00 X | ||||
| Price To Book | 1.69 X | ||||
| Price To Sales | 2.21 X | ||||
| Revenue | 781.43 M | ||||
| Gross Profit | 151.54 M | ||||
| EBITDA | (7.16 M) | ||||
| Net Income | (83.91 M) | ||||
| Cash And Equivalents | 823.67 M | ||||
| Cash Per Share | 2.33 X | ||||
| Total Debt | 626.2 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 5.46 X | ||||
| Cash Flow From Operations | 33.95 M | ||||
| Short Ratio | 2.32 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Price To Earnings To Growth | 3.15 X | ||||
| Target Price | 6.2 | ||||
| Number Of Employees | 5.01 K | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 1.7 B | ||||
| Total Asset | 2.3 B | ||||
| Retained Earnings | (476.29 M) | ||||
| Working Capital | 438.59 M | ||||
| Five Year Return | 4.88 % | ||||
| Net Asset | 2.3 B |
About Evotec SE Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evotec SE ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evotec SE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evotec SE ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving together with Evotec Stock
| 0.74 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Evotec Stock
| 0.91 | PEPG | PepGen | PairCorr |
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.77 | MREO | Mereo BioPharma Group | PairCorr |
| 0.75 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.74 | PDSB | PDS Biotechnology Corp | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Evotec SE Piotroski F Score and Evotec SE Altman Z Score analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 2.1925 | Quarterly Revenue Growth (0.06) | Return On Assets (0.02) | Return On Equity (0.16) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.